Skip to content
Peptigraph home

ZUPREME-3: Petrelintide Phase 3 trial (NCT07843498)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity

Registry record checked

At a glance

Phase
Phase 3
Status
Not yet recruiting
Enrolment
3,900
estimated
Start
30 Sep 2026 (estimated)
Primary completion
21 Dec 2028 (estimated)
Sponsor
Hoffmann-La Roche
Design

Arms and doses

NCT07843498 study arms
ArmTypeInterventionsDescription
PetrelintideExperimentalCombination Product: PetrelintideNot stated
PlaceboPlacebo comparatorCombination Product: PlaceboNot stated
Endpoints

Primary endpoint

NCT07843498 primary outcomes
MeasureTime frame
Percentage Change in Body Weight from BaselineFrom Baseline to Week 64
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07843498 secondary outcomes
MeasureTime frame
Proportion of Participants Achieving ≥ 5% Body Weight Loss from BaselineFrom Baseline to Week 64
Proportion of Participants Achieving ≥ 10% Body Weight Loss from BaselineFrom Baseline to Week 64
Proportion of Participants Achieving ≥ 15% Body Weight Loss from BaselineFrom Baseline to Week 64
Change from Baseline in Waist Circumference (cm)From Baseline to Week 64
Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)From Baseline to Week 64
Change from Baseline in TriglyceridesFrom Baseline to Week 64
Change from Baseline in High-Density Lipoprotein (HDL) CholesterolFrom Baseline to Week 64
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQoL-Lite-CT) Physical Functioning Composite ScoreFrom Baseline to Week 64
Change from Baseline in IWQoL-Lite-CT Physical Functioning Composite Score in Participants with Poor Physical Functioning at Baseline (as defined by Patient Global Impression of Severity/Status [PGI-S])From Baseline to Week 64
Change from Baseline in Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain ScoreFrom Baseline to Week 64
Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score in Participants with Poor Physical Functioning at Baseline (as defined by PGI-S)From Baseline to Week 64
Change from Baseline in Mean Daily Food Craving ScoreFrom Baseline to Week 64
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.